Applicant, as named in the Orange Book

Bdsi

Next listed expiry: Belbuca on 21 Dec 2032. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Belbuca NDA 207932 · 7 strengths buprenorphine hydrochloride	buprenorphine hydrochloride	21 Dec 2032 patent, carve-out possible	patent, carve-out possible
Symproic NDA 208854 naldemedine tosylate	naldemedine tosylate	13 May 2033 patent	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.